Invitrogen™ CD134 (OX40) Monoclonal Antibody (OX-86), PerCP-eFluor™ 710, eBioscience™

Beskrivning

Description: The OX-86 monoclonal antibody reacts with mouse CD134, also known as OX40. A member of the TNF receptor superfamily, CD134 is a 50 kDa type I membrane glycoprotein expressed by activated mouse T lymphocytes. Rat CD134 was initially identified as an activation marker only on activated CD4+ T cells. In contrast, mouse CD134 is expressed by both activated CD4+ and CD8+ T cells. The interaction of CD134 with CD252 (OX40 ligand) has been implicated in T cell-dependent humoral responses, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool, and regulation of tolerance in the CD4+ T cell compartment. Applications Reported: This OX-86 antibody has been reported for use in flow cytometric analysis. Applications Tested: This OX-86 antibody has been tested by flow cytometric analysis of stimulated mouse splenocytes. This can be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. PerCP-eFluor® 710 emits at 710 nm and is excited with the blue laser (488 nm); it can be used in place of PerCP-Cyanine5.5. We recommend using a 710/50 bandpass filter, however, the 695/40 bandpass filter is an acceptable alternative. Please make sur...

OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.